

RN 331822-91-4 HCAPLUS
CN Pseudomycin B, 8-[(3S)-N-cyclobutyl-3-hydroxy-L-asparagine]- (9CI) (CA INDEX NAME)



RN 331822-92-5 HCAPLUS
CN Pseudomycin B, 8-[(3S)-3-hydroxy-N-(2-hydroxyethyl)-L-asparagine]- (9CI) (CA INDEX NAME)



RN 331822-93-6 HCAPLUS
CN Pseudomycin B, 8-[(3S)-N-[2-(dimethylamino)ethyl]-3-hydroxy-L-asparagine]- (9CI) (CA INDEX NAME)



RN 331822-94-7 HCAPLUS
CN Pseudomycin B, 8-[(3S)-N-[3-(dimethylamino)propyl]-3-hydroxy-L-asparagine]- (9CI) (CA INDEX NAME)



RN 331822-95-8 HCAPLUS
CN Pseudomycin B, 8-[(3S)-3-hydroxy-N-(2-methoxy-2-oxoethyl)-L-asparagine]- (9CI) (CA INDEX NAME)



RN 331822-96-9 HCAPLUS
CN Pseudomycin B, 8-[(3S)-3-hydroxy-N-[(1S)-2-methoxy-2-oxo-1-(phenylmethyl)ethyl]-L-asparagine]- (9CI) (CA INDEX NAME)



IT **277758-37-9 319015-31-1**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation and antifungal activity of pseudomycin B amides)
RN 277758-37-9 HCAPLUS
CN Pseudomycin B, 2-[(2R)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]-4-[N6-[(phenylmethoxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B



PAGE 1-C



RN 319015-31-1 HCAPLUS
CN Pseudomycin B, 2-[(2R)-2-amino-4-[[(2-propenyloxy)carbonyl]amino]butanoic acid]-4-[N6-[(2-propenyloxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(2-propenyloxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B





REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L59 ANSWER 11 OF 26 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:64019 HCAPLUS
DOCUMENT NUMBER: 134:101199
TITLE: Preparation of pseudomycin amide and ester analogs
INVENTOR(S): Chen, Shu Hui; Galka, Christopher Stanley; Hellman, Sarah Lynne; Krstenansky, John L.; Rodriguez, Michael John; Sun, Xicheng David; Usyatinsky, Alexander Ya.; Vasudevan, Venkatraghavan; Zweifel, Mark James
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001005817	A1	20010125	WO 2000-US15021	20000608
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000013163	A	20020402	BR 2000-13163	20000608
EP 1198473	A1	20020424	EP 2000-942656	20000608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003505399	T2	20030212	JP 2001-511474	20000608
NO 2002000186	A	20020304	NO 2002-186	20020114
PRIORITY APPLN. INFO.:			US 1999-143981P P	19990715
			WO 2000-US15021 W	20000608

OTHER SOURCE(S): MARPAT 134:101199
GI



I

AB Pseudomycin analogs I [R is a substituent having alkyl, acylaminomethyl, Ph, phenylhydroxyalkyl, or 3-pyridyl radicals of defined structure; R1 = NH2 or protected amino; R2, R3 = OH, alkoxy, cycloalkyloxy, an amino group or amino acid residue, etc.] and their pharmaceutically acceptable salts were prepared for use as antifungal agents. Thus, Cbz-protected pseudomycin B was treated with ethanol or cyclopropylamine to yield the di-Et ester and the monocyclopropylamide (COR2-position), resp., following deprotection. Fungicidal activity as a function of amidation position is discussed.

IT **319497-03-5P 319497-04-6P 319497-05-7P**
319497-06-8P 319497-07-9P 319497-10-4P
319497-12-6P 319497-16-0P 319497-17-1P
319497-19-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pseudomycin amide and ester analogs)

RN 319497-03-5 HCAPLUS
CN Pseudomycin B, diethyl ester (9CI) (CA INDEX NAME)



RN 319497-04-6 HCAPLUS
CN Pseudomycin B, dipropyl ester (9CI) (CA INDEX NAME)



RN 319497-05-7 HCAPLUS
CN Pseudomycin B, 3-pentyl ester (9CI) (CA INDEX NAME)



RN 319497-06-8 HCAPLUS
CN Pseudomycin B, 8-pentyl ester (9CI) (CA INDEX NAME)



RN 319497-07-9 HCAPLUS
CN Pseudomycin B, 3-L-asparagine- (9CI) (CA INDEX NAME)



RN 319497-10-4 HCAPLUS
CN Pseudomycin B, 3-(N-cyclopropyl-L-asparagine)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 319497-12-6 HCAPLUS
CN Pseudomycin B, 3-[N-(3-pyridinylmethyl)-L-asparagine]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 319497-16-0 HCAPLUS
CN Pseudomycin B, 8-[(3S)-N-butyl-3-hydroxy-L-asparagine]- (9CI) (CA INDEX NAME)



RN 319497-17-1 HCAPLUS
CN Pseudomycin B, 8-[(3S)-3-hydroxy-N-[2-(4-morpholinyl)ethyl]-L-asparagine]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 319497-19-3 HCAPLUS
CN Pseudomycin B, 3-(N-heptyl-L-asparagine)- (9CI) (CA INDEX NAME)



IT **139203-13-7,** Pseudomycin a **277758-37-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pseudomycin amide and ester analogs)
RN 139203-13-7 HCAPLUS
CN Pseudomycin A (9CI) (CA INDEX NAME)



RN 277758-37-9 HCAPLUS
CN Pseudomycin B, 2-[(2R)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]-4-[N6-[(phenylmethoxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B



PAGE 1-C



IT **319015-31-1P 319497-02-4P 319497-08-0P**
319497-09-1P 319497-11-5P 319497-13-7P
319497-14-8P 319497-15-9P 319497-18-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pseudomycin amide and ester analogs)

RN 319015-31-1 HCAPLUS

CN Pseudomycin B, 2-[(2R)-2-amino-4-[[(2-propenyloxy)carbonyl]amino]butanoic acid]-4-[N6-[(2-propenyloxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(2-propenyloxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B



PAGE 1-C



RN 319497-02-4 HCAPLUS
CN Pseudomycin A, 2-[(2R)-2-amino-4-[[(2-propenyloxy)carbonyl]amino]butanoic acid]-4-[N6-[(2-propenyloxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(2-propenyloxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B



PAGE 1-C





RN 319497-08-0 HCAPLUS
CN Pseudomycin B, 2-[(2R)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]-3-L-asparagine-4-[N6-[(phenylmethoxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B



PAGE 1-C



RN 319497-09-1 HCAPLUS
CN Pseudomycin B, 2-[(2R)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]-3-(N-cyclopropyl-L-asparagine)-4-[N6-[(phenylmethoxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B



PAGE 1-C



RN 319497-11-5 HCAPLUS
CN Pseudomycin B, 2-[(2R)-2-amino-4-[[(2-propenyloxy)carbonyl]amino]butanoic acid]-3-(N-cyclopropyl-L-asparagine)-4-[N6-[(2-propenyloxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(2-propenyloxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B



PAGE 1-C



RN 319497-13-7 HCAPLUS
CN Pseudomycin B, 2-[(2R)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]-3-[N-(3-pyridinylmethyl)-L-asparagine]-4-[N6-[(phenylmethoxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B



PAGE 1-C



PAGE 2-B



RN 319497-14-8 HCAPLUS
CN Pseudomycin B, 2-[(2R)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]-3-[N-[(1S)-5-amino-1-(methoxycarbonyl)pentyl]-L-asparagine]-4-[N6-[(phenylmethoxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B



PAGE 1-C



RN 319497-15-9 HCAPLUS
CN Pseudomycin B, 2-[(2R)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]-4-[N6-[(phenylmethoxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]-8-[(3S)-N-butyl-3-hydroxy-L-asparagine]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A





PAGE 1-B



PAGE 1-C



RN 319497-18-2 HCAPLUS
CN Pseudomycin B, 2-[(2R)-2-amino-4-[[(2-propenyloxy)carbonyl]amino]butanoic acid]-4-[N6-[(2-propenyloxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(2-propenyloxy)carbonyl]amino]butanoic acid]-8-[(3S)-3-hydroxy-N-[2-(4-morpholinyl)ethyl]-L-asparagine]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B



PAGE 1-C



PAGE 2-B



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L59 ANSWER 12 OF 26 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:64018 HCAPLUS
DOCUMENT NUMBER: 134:101198
TITLE: Preparation of amine-modified pseudomycin compounds
INVENTOR(S): Chen, Shu Hui; Jamison, James Andrew; Rodriguez, Michael John; Sun, Xicheng David; Vasudevan, Venkatraghavan; Zweifel, Mark James
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001005816	A1	20010125	WO 2000-US15019	20000608
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000013168	A	20020402	BR 2000-13168	20000608
EP 1198472	A1	20020424	EP 2000-939447	20000608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003505398	T2	20030212	JP 2001-511473	20000608
NO 2002000194	A	20020314	NO 2002-194	20020114
PRIORITY APPLN. INFO.:			US 1999-143839P P	19990715
			WO 2000-US15019 W	20000608

OTHER SOURCE(S): MARPAT 134:101198
GI



I

AB Amine-modified pseudomycin compds. I [R is a substituent having alkyl, acylaminomethyl, Ph, phenylhydroxyalkyl, or 3-pyridyl radicals of defined structure; R1 = H, formyl, acylalkyl, acylalkylamine, acylazaalkyl, acyloxyalkene, acyloxyaryl, or acylmethylenecarbamate, provided that at least one R1 is not H; R2, R3 = OH, alkoxy, cycloalkyloxy, an amino group or amino acid residue, etc.] and their pharmaceutically acceptable salts were prepared for use as antifungal agents. Thus, pseudomycin B was treated with Cbz-Gly-ONSu (Cbz = benzyloxycarbonyl, NSU = succinimide residue) to yield the N,N',N''-tri-glycyl derivative, following deprotection.

IT **139203-14-8**, Pseudomycin b
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of amine-modified pseudomycin compds.)

RN 139203-14-8 HCAPLUS

CN Pseudomycin B (9CI) (CA INDEX NAME)



IT **319015-35-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amine-modified pseudomycin compds.)
RN 319015-35-5 HCAPLUS
CN Pseudomycin B, 2-[N4-[N-[(phenylmethoxy)carbonyl]glycyl]-(2R)-2,4-diaminobutanoic acid]-4-[N6-[N-[(phenylmethoxy)carbonyl]glycyl]-L-lysine]-5-[N4-[N-[(phenylmethoxy)carbonyl]glycyl]-(2S)-2,4-diaminobutanoic acid]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B



PAGE 1-C



IT **319015-20-8P 319015-27-5P 319015-31-1P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amine-modified pseudomycin compds.)
RN 319015-20-8 HCAPLUS
CN Pseudomycin B, 2-[N4-glycyl-(2R)-2,4-diaminobutanoic acid]-4-(N6-glycyl-L-lysine)-5-[N4-glycyl-(2S)-2,4-diaminobutanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B



PAGE 1-C



RN 319015-27-5 HCAPLUS
CN Pseudomycin B, 2-[(2R)-2-amino-4-[(phenoxycarbonyl)amino]butanoic acid]-4-[N6-(phenoxycarbonyl)-L-lysine]-5-[(2S)-2-amino-4-[(phenoxycarbonyl)amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B



PAGE 1-C



RN 319015-31-1 HCAPLUS
CN Pseudomycin B, 2-[(2R)-2-amino-4-[[(2-propenyloxy)carbonyl]amino]butanoic acid]-4-[N6-[(2-propenyloxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(2-propenyloxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B





REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L59 ANSWER 13 OF 26 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:64017 HCAPLUS
DOCUMENT NUMBER: 134:101197
TITLE: Process for deacylation of lipodepsipeptides
INVENTOR(S): Kreuzman, Adam Joseph; Kulanthaivel, Palaniappan; Rodriguez, Michael John
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001005815	A1	20010125	WO 2000-US15018	20000608
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000012481	A	20020402	BR 2000-12481	20000608
EP 1198471	A1	20020424	EP 2000-938006	20000608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003505042	T2	20030212	JP 2001-511472	20000608
NO 2002000183	A	20020313	NO 2002-183	20020114
PRIORITY APPLN. INFO.:			US 1999-143968P P	19990715
			WO 2000-US15018 W	20000608

OTHER SOURCE(S): CASREACT 134:101197
AB A process for deacylating an N-acyl side chain of a pseudomycin natural

product comprises reacting the pseudomycin with a deacylating enzyme to produce the pseudomycin nucleus. Thus, treating pseudomycin A with purified ECB deacylase in aqueous buffered solution afforded a compound (C37H61ClN12O17) resulting from cleavage of the 2,4-dihydroxytetradecanoyl group and an isomer resulting from rearrangement of the pseudomycin hydroxy nucleus [OCH2CHNH2 → NHCH(CH2OH)].

IT **139203-13-7**, Pseudomycin a **139203-14-8**, Pseudomycin b
139203-15-9, Pseudomycin c **162443-73-4**, Pseudomycin c'
301533-14-2, Pseudomycin A' **301533-15-3**, Pseudomycin B'
RL: RCT (Reactant); RACT (Reactant or reagent)
(deacylation of lipodepsipeptides)

RN 139203-13-7 HCAPLUS
CN Pseudomycin A (9CI) (CA INDEX NAME)



RN 139203-14-8 HCAPLUS
CN Pseudomycin B (9CI) (CA INDEX NAME)



RN 139203-15-9 HCAPLUS
CN Pseudomycin C (9CI) (CA INDEX NAME)



RN 162443-73-4 HCAPLUS
CN Pseudomycin C' (9CI) (CA INDEX NAME)



RN 301533-14-2 HCAPLUS
CN L-Threonine, N-(3,4-dihydroxy-1-oxopentadecyl)-L-seryl-(2R)-2,4-diaminobutanoyl-L-α-aspartyl-L-lysyl-(2S)-2,4-diaminobutanoyl-L-allothreonyl-(2Z)-2-amino-2-butenoyl-(3S)-3-hydroxy-L-α-aspartyl-4-chloro-, (9→13)-lactone (9CI) (CA INDEX NAME)



RN 301533-15-3 HCAPLUS
CN L-Threonine, N-(3-hydroxy-1-oxododecyl)-L-seryl-(2R)-2,4-diaminobutanoyl-L-α-aspartyl-L-lysyl-(2S)-2,4-diaminobutanoyl-L-allothreonyl-(2Z)-2-amino-2-butenoyl-(3S)-3-hydroxy-L-α-aspartyl-4-chloro-, (9→13)-lactone (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L59 ANSWER 14 OF 26 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:64016 HCAPLUS
DOCUMENT NUMBER: 134:116242
TITLE: Preparation of pseudomycin N-acyl side-chain analogs
INVENTOR(S): Belvo, Matthew David; Chen, Shu Hui; Doecke, Christopher William; Hellman, Sarah Lynne; Jamison, James Andrew; Patterson, Lawrence Edward; Rodriguez, Lawrence Edward; Sun, Xicheng David; Turner, William Wilson; Vasudevan, Venkatraghavan; Zweifel, Mark James
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001005814	A1	20010125	WO 2000-US15017	20000608
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000012447	A	20020402	BR 2000-12447	20000608
EP 1200460	A1	20020502	EP 2000-942655	20000608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003505397	T2	20030212	JP 2001-511471	20000608
NO 2002000193	A	20020314	NO 2002-193	20020114
PRIORITY APPLN. INFO.:			US 1999-143989P P	19990715
			WO 2000-US15017 W	20000608

OTHER SOURCE(S): MARPAT 134:116242
GI



I

AB Pseudomycin analogs I [R is a substituent having alkyl, acylaminomethyl, Ph, phenylhydroxyalkyl, or 3-pyridyl radicals of defined structure] and their stereoisomers and pharmaceutically acceptable salts were prepared for use as antifungal agents. Thus, treating Cbz-protected pseudomycin nucleus with 3-(3-dodecylphenyl)-3-hydroxypropanoic acid (Q-OH, preparation given) and deprotection afforded I (R = Q) as a mixture of diastereomers.

IT **321581-66-2P 321581-78-6P 321581-79-7P**
321581-87-7P 321581-91-3P 321581-97-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pseudomycin N-acyl side-chain analogs)

RN 321581-66-2 HCAPLUS

CN Pseudomycin A, 1-[N-(1-oxotetradecyl)-L-serine]-2-[(2R)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]-4-[N6-[(phenylmethoxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B



PAGE 1-C



RN 321581-78-6 HCAPLUS
CN Pseudomycin A, 1-[N-[(3R)-3-(3-dodecylphenyl)-3-hydroxy-1-oxopropyl]-L-serine]-2-[(2R)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]-4-[N6-[(phenylmethoxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B



PAGE 1-C



RN 321581-79-7 HCAPLUS
CN Pseudomycin A, 1-[N-[(3S)-3-(3-dodecylphenyl)-3-hydroxy-1-oxopropyl]-L-serine]-2-[(2R)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]-4-[N6-[(phenylmethoxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B



PAGE 1-C



RN 321581-87-7 HCAPLUS
CN Pseudomycin A, 1-[N-[(3R)-1-oxo-3-[[(phenylmethoxy)carbonyl]amino]tetradecyl]-L-serine]-2-[(2R)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]-4-[N6-[(phenylmethoxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B



PAGE 1-C



RN 321581-91-3 HCAPLUS
CN Pseudomycin A, 1-[N-[(3R,13Z)-3-hydroxy-2,2-dimethyl-1-oxo-13-octadecenyl]-L-serine]-2-[(2R)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]-4-[N6-[(phenylmethoxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B



PAGE 1-C



RN 321581-97-9 HCAPLUS
CN Pseudomycin A, 1-[N-[(3R)-3-hydroxy-2,2-dimethyl-1-oxo-10,12-tetradecadienyl]-L-serine]-2-[(2R)-2-amino-4-[[(2-propenyloxy)carbonyl]amino]butanoic acid]-4-[N6-[(2-propenyloxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(2-propenyloxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

PAGE 1-A



PAGE 1-B



PAGE 1-C



IT **307498-31-3P 307498-34-6P 321581-80-0P**
321581-81-1P 321581-86-6P 321581-90-2P
321581-96-8P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pseudomycin N-acyl side-chain analogs)

RN 307498-31-3 HCAPLUS

CN Pseudomycin A, 1-[N-[(3S)-3-(3-dodecylphenyl)-3-hydroxy-1-oxopropyl]-L-serine]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 307498-34-6 HCAPLUS
CN Pseudomycin A, 1-[N-[(3R)-3-(3-dodecylphenyl)-3-hydroxy-1-oxopropyl]-L-serine]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 321581-80-0 HCAPLUS
CN Pseudomycin A, 1-[N-[3-(3-dodecylphenyl)-1-oxo-2-propenyl]-L-serine]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 321581-81-1 HCAPLUS
CN Pseudomycin A, 1-(N-tridecylglycyl-L-serine)- (9CI) (CA INDEX NAME)



RN 321581-86-6 HCAPLUS
CN Pseudomycin A, 1-[N-[(3R)-3-amino-1-oxotetradecyl]-L-serine]- (9CI) (CA INDEX NAME)



RN 321581-90-2 HCAPLUS
CN Pseudomycin A, 1-[N-[(3R,13Z)-3-hydroxy-2,2-dimethyl-1-oxo-13-octadecenyl]-L-serine]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

$-NH_2$

RN 321581-96-8 HCAPLUS
CN Pseudomycin A, 1-[N-[(3R)-3-hydroxy-2,2-dimethyl-1-oxo-10,12-tetradecadienyl]-L-serine]- (9CI) (CA INDEX NAME)

PAGE 1-A





RN 301533-15-3 HCAPLUS
CN L-Threonine, N-(3-hydroxy-1-oxododecyl)-L-seryl-(2R)-2,4-diaminobutanoyl-L-α-aspartyl-L-lysyl-(2S)-2,4-diaminobutanoyl-L-allothreonyl-(2Z)-2-amino-2-butenoyl-(3S)-3-hydroxy-L-α-aspartyl-4-chloro-, (9→13)-lactone (9CI) (CA INDEX NAME)



RN 303127-72-2 HCAPLUS
CN Pseudomycin B, hydrate (9CI) (CA INDEX NAME)



● x H_2O

L59 ANSWER 19 OF 26 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:619252 HCAPLUS
DOCUMENT NUMBER: 134:5138
TITLE: Syntheses and biological evaluation of novel pseudomycin side-chain analogs. Part 2
AUTHOR(S): Chen, S.-H.; Sun, X.; Boyer, R.; Paschal, J.; Zeckner, D.; Current, W.; Zweifel, M.; Rodriguez, M.
CORPORATE SOURCE: Lilly Corporate Center, A Division of Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, IN, 46285, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2000), 10(18), 2107-2110
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 134:5138

AB A series of aliphatic side-chain analogs of pseudomycin was synthesized and biol. evaluated. We found that several of the pseudomycin side-chain analogs exhibited good in vitro activity against all three major fungi responsible for systemic fungal infections.

IT **139203-14-8P**, Pseudomycin B **307557-76-2P** **307557-77-3P** **307557-78-4P** **307557-79-5P** **307557-80-8P** **307557-81-9P** **308110-73-8P**, 3'-epi-Pseudomycin B **308110-74-9P**, 3'-rac-Pseudomycin B
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of pseudomycin side-chain analogs as fungicides)

RN 139203-14-8 HCAPLUS
CN Pseudomycin B (9CI) (CA INDEX NAME)



RN 307557-76-2 HCAPLUS
CN Pseudomycin A, 1-[N-[(3R)-3-hydroxy-1-oxooctadecyl]-L-serine]- (9CI) (CA INDEX NAME)



RN 307557-77-3 HCAPLUS
CN Pseudomycin A, 1-[N-[(3S)-3-hydroxy-1-oxooctadecyl]-L-serine]- (9CI) (CA INDEX NAME)



RN 307557-78-4 HCAPLUS
CN Pseudomycin A, 1-[N-(3-hydroxy-1-oxooctadecyl)-L-serine]- (9CI) (CA INDEX NAME)



RN 307557-79-5 HCAPLUS
CN Pseudomycin A, 1-[N-[(3R)-3-hydroxy-1-oxoeicosyl]-L-serine]- (9CI) (CA INDEX NAME)



RN 307557-80-8 HCAPLUS
CN Pseudomycin A, 1-[N-[(3S)-3-hydroxy-1-oxoeicosyl]-L-serine]- (9CI) (CA INDEX NAME)



RN 307557-81-9 HCAPLUS
CN Pseudomycin A, 1-[N-(3-hydroxy-1-oxoeicosyl)-L-serine]- (9CI) (CA INDEX NAME)



RN 308110-73-8 HCAPLUS
CN Pseudomycin B, 1-[N-[(3S)-3-hydroxy-1-oxotetradecyl]-L-serine]- (9CI) (CA INDEX NAME)



RN 308110-74-9 HCAPLUS
CN Pseudomycin B, 1-[N-(3-hydroxy-1-oxotetradecyl)-L-serine]- (9CI) (CA INDEX NAME)



IT **307557-83-1P 307557-85-3P 307557-86-4P 307557-87-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pseudomycin side-chain analogs as fungicides)
RN 307557-83-1 HCAPLUS
CN Pseudomycin A, 1-[N-[(3R)-3-hydroxy-1-oxooctadecyl]-L-serine]-2-[(2R)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]-4-[N6-[(phenylmethoxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B



PAGE 1-C



RN 307557-85-3 HCAPLUS
CN Pseudomycin B, 1-[N-(3-hydroxy-1-oxotetradecyl)-L-serine]-2-[(2R)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]-4-[N6-[(phenylmethoxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

-- $(CH_2)_4-NH_2$

—— NH_2

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L59 ANSWER 15 OF 26 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:64015 HCAPLUS
DOCUMENT NUMBER: 134:116241
TITLE: Preparation of pseudomycin **prodrugs**
INVENTOR(S): Chen, Shu Hui; Rodriguez, Michael John; Sun, Xicheng David
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001005813	A1	20010125	WO 2000-US15016	20000608
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000013153	A	20020402	BR 2000-13153	20000608
EP 1198470	A1	20020424	EP 2000-938005	20000608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003505396	T2	20030212	JP 2001-511470	20000608
NO 2002000192	A	20020314	NO 2002-192	20020114

PRIORITY APPLN. INFO.: US 1999-143840P P 19990715
WO 2000-US15016 W 20000608

OTHER SOURCE(S): MARPAT 134:116241
GI



I

AB Pseudomycin **prodrugs** I [R is a substituent having alkyl, acylaminomethyl, Ph, phenylhydroxyalkyl, or 3-pyridyl radicals of defined structure; R1 = H, acyloxymethylene-1,3-dioxolen-2-one, or acyloxymethylenecarboxylate; R2, R3 = OH, alkoxy, cycloalkyloxy, an amino group or amino acid residue, etc.] and their pharmaceutically acceptable salts were prepared for use as antifungal agents. Thus, pseudomycin C' was treated with 5-methyl-1,3-dioxolen-2-one-4-ylmethyl p-nitrophenyl carbonate (preparation given) to yield mono-, di-, and tri-substituted acyloxyalkylcarbamate **prodrugs** which were assayed for tail vein toxicity.

IT **321156-55-2P 321156-56-3P 321156-57-4P**
321156-58-5P 321156-60-9P 321198-86-1P
321198-87-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pseudomycin **prodrugs**)

RN 321156-55-2 HCAPLUS

CN Pseudomycin C', 2-[(2R)-2-amino-4-[[[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy]carbonyl]amino]butanoic acid]-4-[N6-[[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy]carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy]carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



PAGE 2-B



RN 321156-56-3 HCAPLUS
CN Pseudomycin B, 5-[(2S)-2-amino-4-[[[(acetyloxy)methoxy]carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 321156-57-4 HCAPLUS
CN Pseudomycin B, 2-[(2R)-2-amino-4-[[[(acetyloxy)methoxy]carbonyl]amino]butanoic acid]-4-[N6-[[(acetyloxy)methoxy]carbonyl]-L-lysine]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



RN 321156-58-5 HCAPLUS
CN Pseudomycin B, 2-[(2R)-2-amino-4-[[[(acetyloxy)methoxy]carbonyl]amino]butanoic acid]-4-[N6-[[(acetyloxy)methoxy]carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[[(acetyloxy)methoxy]carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B



PAGE 1-C



PAGE 2-A



RN 321156-60-9 HCAPLUS
CN Pseudomycin B, 2-[(2R)-2-amino-4-[[[(2,2-dimethyl-1-oxopropoxy)methoxy]carbonyl]amino]butanoic acid]-3-(N-cyclopropyl-L-asparagine)-4-[N6-[[(2,2-dimethyl-1-oxopropoxy)methoxy]carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[[(2,2-dimethyl-1-oxopropoxy)methoxy]carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B



PAGE 1-C



RN 321198-86-1 HCAPLUS
CN Pseudomycin C', monoamide with 4-[(carboxyoxy)methyl]-5-methyl-1,3-dioxol-2-one (9CI) (CA INDEX NAME)

CM 1

CRN 321198-85-0

CMF C6 H6 O6



CM 2

CRN 162443-73-4
CMF C53 H91 Cl N12 O19



RN 321198-87-2 HCAPLUS
CN Pseudomycin C', diamide with 4-[(carboxyoxy)methyl]-5-methyl-1,3-dioxol-2-one (9CI) (CA INDEX NAME)

CM 1

CRN 321198-85-0
CMF C6 H6 O6



CM 2

CRN 162443-73-4
CMF C53 H91 Cl N12 O19



IT **139203-14-8,** Pseudomycin b **162443-73-4,** Pseudomycin c' **321156-59-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pseudomycin **prodrugs**)
RN 139203-14-8 HCAPLUS
CN Pseudomycin B (9CI) (CA INDEX NAME)



RN 162443-73-4 HCAPLUS
CN Pseudomycin C' (9CI) (CA INDEX NAME)



RN 321156-59-6 HCAPLUS
CN Pseudomycin B, 2-[(2R)-2-amino-4-[[[(2,2-dimethyl-1-oxopropoxy)methoxy]carbonyl]amino]butanoic acid]-4-[N6-[[(2,2-dimethyl-1-oxopropoxy)methoxy]carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[[(2,2-dimethyl-1-oxopropoxy)methoxy]carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B



PAGE 1-C



IT **277758-37-9P 307557-76-2P 307557-83-1P**
319497-03-5P 319497-09-1P 319497-10-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pseudomycin **prodrugs**)

RN 277758-37-9 HCAPLUS

CN Pseudomycin B, 2-[(2R)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]-4-[N6-[(phenylmethoxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B





RN 307557-76-2 HCAPLUS
CN Pseudomycin A, 1-[N-[(3R)-3-hydroxy-1-oxooctadecyl]-L-serine]- (9CI) (CA INDEX NAME)



RN 307557-83-1 HCAPLUS
CN Pseudomycin A, 1-[N-[(3R)-3-hydroxy-1-oxooctadecyl]-L-serine]-2-[(2R)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]-4-[N6-[(phenylmethoxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B





RN 319497-03-5 HCAPLUS
CN Pseudomycin B, diethyl ester (9CI) (CA INDEX NAME)



RN 319497-09-1 HCAPLUS
CN Pseudomycin B, 2-[(2R)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]-3-(N-cyclopropyl-L-asparagine)-4-[N6-[(phenylmethoxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B



PAGE 1-C



RN 319497-10-4 HCAPLUS
CN Pseudomycin B, 3-(N-cyclopropyl-L-asparagine)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L59 ANSWER 16 OF 26 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:756829 HCAPLUS
DOCUMENT NUMBER: 133:309068

TITLE: Pseudomycin production by Pseudomonas syringae
INVENTOR(S): Hilton, Matthew Dale; Strobel, Robert Joseph, Jr.; Millar, Penelope Jane Beverly; Thomas, Dennis Nelson; Cockshott, Andrew Richard; Getman, Brian Gerald; Eastridge, Jack Richard; Cantwell, Cathleen Alice
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000063345	A1	20001026	WO 2000-US8728	20000414
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1171576	A1	20020116	EP 2000-921594	20000414
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000010614	A	20020213	BR 2000-10614	20000414
JP 2002542262	T2	20021210	JP 2000-612424	20000414
NO 2001004989	A	20011109	NO 2001-4989	20011012

PRIORITY APPLN. INFO.: US 1999-129431P P 19990415
WO 2000-US8728 W 20000414

GI



I

AB A process for producing one or more pseudomycins is described including cultures of Pseudomonas syringae that produce one or more pseudomycins having general formula (I) where R is a lipophilic moiety. Thus, Pseudomonas syringae strain 67H1 produced pseudomycins A, B, C, and C' at concns. of 243, 203, 71 and 40 mg/L resp. in a 5000 L fed batch fermentation The pseudomycins were then recovered from the harvested fermentation broth by microfiltration to remove cells followed by solvent extraction Extracted pseudomycins were further purified by ion exchange and reverse phase liquid chromatog.

IT **139203-13-7P**, Pseudomycin A **139203-14-8P**, Pseudomycin B **139203-15-9P**, Pseudomycin C **162443-73-4P**, Pseudomycin C' **301533-14-2P**, Pseudomycin A' **301533-15-3P**, Pseudomycin B'
RL: BMF (Bioindustrial manufacture); BPN (Biosynthetic preparation); PUR (Purification or recovery); BIOL (Biological study); PREP (Preparation)
(Pseudomycin production by Pseudomonas syringae)

RN 139203-13-7 HCAPLUS

CN Pseudomycin A (9CI) (CA INDEX NAME)



RN 139203-14-8 HCAPLUS
CN Pseudomycin B (9CI) (CA INDEX NAME)



RN 139203-15-9 HCAPLUS
CN Pseudomycin C (9CI) (CA INDEX NAME)



RN 162443-73-4 HCAPLUS
CN Pseudomycin C' (9CI) (CA INDEX NAME)



RN 301533-14-2 HCAPLUS
CN L-Threonine, N-(3,4-dihydroxy-1-oxopentadecyl)-L-seryl-(2R)-2,4-diaminobutanoyl-L-α-aspartyl-L-lysyl-(2S)-2,4-diaminobutanoyl-L-allothreonyl-(2Z)-2-amino-2-butenoyl-(3S)-3-hydroxy-L-α-aspartyl-4-chloro-, (9→13)-lactone (9CI) (CA INDEX NAME)



RN 301533-15-3 HCAPLUS
CN L-Threonine, N-(3-hydroxy-1-oxododecyl)-L-seryl-(2R)-2,4-diaminobutanoyl-L-α-aspartyl-L-lysyl-(2S)-2,4-diaminobutanoyl-L-allothreonyl-(2Z)-2-amino-2-butenoyl-(3S)-3-hydroxy-L-α-aspartyl-4-chloro-, (9→13)-lactone (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L59 ANSWER 17 OF 26 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:756734 HCAPLUS
DOCUMENT NUMBER: 133:295439
TITLE: Pseudomycin antifungal natural products
INVENTOR(S): Kulanthaivel, Palaniappan; Belvo, Matthew David; Martin, James William; Perun, Thomas John, Jr.; Zeckner, Douglas Joseph
PATENT ASSIGNEE(S): Eli Lilly and Co., USA; Perun, Thomas John, Jr.
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000063237	A2	20001026	WO 2000-US8727	20000414
WO 2000063237	A3	20010104		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1173471	A2	20020123	EP 2000-921593	20000414
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000009731	A	20020305	BR 2000-9731	20000414
JP 2002542257	T2	20021210	JP 2000-612327	20000414
NO 2001004937	A	20011213	NO 2001-4937	20011010
US 6630147	B1	20031007	US 2001-958995	20011015
US 2004067879	A1	20040408	US 2003-636376	20030807

PRIORITY APPLN. INFO.:

US 1999-129447P	P	19990415
WO 2000-US8727	W	20000414
US 2001-958995	A3	20011015

AB The invention discloses a process for the production of the antifungal natural products pseudomycin A' and pseudomycin B' by Pseudomonas syringae and the various methods for employing the antifungal activity of these pseudomycins. Pseudomycins A' and B' exhibit antifungal activity against Candida albicans, Candida parapsilosis, Cryptococcus neoformans, Aspergillus fumigatus, and Histoplasma capsulatum. NMR and mass spectrometry indicate structure for pseudomycin A' and structure for pseudomycin B'. Also covered in the claims is the administration of these compds. and their salts by means of capsules, aerosols, tablets, suppositories and i.v. solns.

IT **301533-14-2P**, Pseudomycin A' **301533-15-3P**, Pseudomycin B'
RL: BMF (Bioindustrial manufacture); BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pseudomycin antifungal natural products)

RN 301533-14-2 HCAPLUS

CN L-Threonine, N-(3,4-dihydroxy-1-oxopentadecyl)-L-seryl-(2R)-2,4-diaminobutanoyl-L-α-aspartyl-L-lysyl-(2S)-2,4-diaminobutanoyl-L-allothreonyl-(2Z)-2-amino-2-butenoyl-(3S)-3-hydroxy-L-α-aspartyl-4-chloro-, (9→13)-lactone (9CI) (CA INDEX NAME)



RN 301533-15-3 HCAPLUS
CN L-Threonine, N-(3-hydroxy-1-oxododecyl)-L-seryl-(2R)-2,4-diaminobutanoyl-L-α-aspartyl-L-lysyl-(2S)-2,4-diaminobutanoyl-L-allothreonyl-(2Z)-2-amino-2-butenoyl-(3S)-3-hydroxy-L-α-aspartyl-4-chloro-, (9→13)-lactone (9CI) (CA INDEX NAME)



L59 ANSWER 18 OF 26 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:756539 HCAPLUS
DOCUMENT NUMBER: 133:325645
TITLE: Pseudomycin antifungal compositions and methods for their use
INVENTOR(S): Vasudevan, Venkatraghavan; Jones, Thomas Warren; Rodriguez, Michael John; Sweetana, Stephanie Ann
PATENT ASSIGNEE(S): Eli Lilly and Co., USA
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000062793	A2	20001026	WO 2000-US8725	20000414
WO 2000062793	A3	20010118		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000009778	A	20020102	BR 2000-9778	20000414
EP 1171150	A2	20020116	EP 2000-923108	20000414
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002542201	T2	20021210	JP 2000-611929	20000414
NO 2001004988	A	20011203	NO 2001-4988	20011012
PRIORITY APPLN. INFO.:			US 1999-129435P	P 19990415
			WO 2000-US8725	W 20000414

OTHER SOURCE(S): MARPAT 133:325645

AB Methods and compns. for treating fungal infections that include formulations of a pseudomycin or related lipodepsidecapeptide antifungal agent and a cyclodextrin are described. The compns. are particularly useful in pharmaceutical applications to reduce adverse effects. Pseudomycin B (50 mg/kg/day) was administered for 14 days to rats as an i.v. bolus in either 4 weight% hydroxypropyl-β-cyclodextrin (HPCD) or γ-cyclodextrin in pH 5.0 acetate buffer. The HPCD vehicle provided protection from adverse effects of pseudomycin B. As a result, daily doses of the HPCD formulation were administered for the full 2 wk of the study. There was some evidence of slight adverse effect at the site of injection at the cross microscopic level. However, γ-CD vehicle did not provide adequate protection from adverse effects of pseudomycin B in this study. After only the first dose swelling and discoloration of the tail was noted becoming severe enough to prevent dosing by day 2.

IT **139203-13-7**, Pseudomycin A **139203-14-8**, Pseudomycin B
139203-15-9, Pseudomycin C **162443-73-4**, Pseudomycin C'
301533-14-2, Pseudomycin A' **301533-15-3**, Pseudomycin B'
303127-72-2, Pseudomycin B hydrate
RL: ADV (Adverse effect, including toxicity); AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antifungal compns. containing pseudomycin or related lipodepsidecapeptide and cyclodextrin)

RN 139203-13-7 HCAPLUS
CN Pseudomycin A (9CI) (CA INDEX NAME)



RN 139203-14-8 HCAPLUS
CN Pseudomycin B (9CI) (CA INDEX NAME)



RN 139203-15-9 HCAPLUS
CN Pseudomycin C (9CI) (CA INDEX NAME)



RN 162443-73-4 HCAPLUS
CN Pseudomycin C' (9CI) (CA INDEX NAME)



RN 301533-14-2 HCAPLUS
CN L-Threonine, N-(3,4-dihydroxy-1-oxopentadecyl)-L-seryl-(2R)-2,4-diaminobutanoyl-L-α-aspartyl-L-lysyl-(2S)-2,4-diaminobutanoyl-L-allothreonyl-(2Z)-2-amino-2-butenoyl-(3S)-3-hydroxy-L-α-aspartyl-4-chloro-, (9→13)-lactone (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 1-B



PAGE 1-C



RN 307557-86-4 HCAPLUS
CN Pseudomycin A, 1-[N-(3-hydroxy-1-oxooctadecyl)-L-serine]-2-[(2R)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]-4-[N6-[(phenylmethoxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B



PAGE 1-C



RN 307557-87-5 HCAPLUS
CN Pseudomycin A, 1-[N-(3-hydroxy-1-oxoeicosyl)-L-serine]-2-[(2R)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]-4-[N6-[(phenylmethoxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B



PAGE 1-C



IT **277758-37-9P 307557-84-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of pseudomycin side-chain analogs as fungicides)
RN 277758-37-9 HCAPLUS
CN Pseudomycin B, 2-[(2R)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]-4-[N6-[(phenylmethoxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B



PAGE 1-C



RN 307557-84-2 HCAPLUS
CN Pseudomycin B, 1-[N-[(3S)-3-hydroxy-1-oxotetradecyl]-L-serine]-2-[(2R)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]-4-[N6-[(phenylmethoxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B





REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L59 ANSWER 20 OF 26 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:619251 HCAPLUS
DOCUMENT NUMBER: 133:362946
TITLE: Syntheses and antifungal activity of pseudomycin side-chain analogs. Part 1
AUTHOR(S): Jamison, J.; Levy, S.; Sun, X.; Zeckner, D.; Current, W.; Zweifel, M.; Rodriguez, M.; Turner, W.; Chen, S.-H.
CORPORATE SOURCE: Lilly Corporate Center, A Division of Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, IN, 46285, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2000), 10(18), 2101-2105
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 133:362946

AB We have described herein the syntheses of three novel series of aromatic ring containing pseudomycin side-chain analogs. Preliminary biol. evaluations of these analogs clearly indicate that it is possible to synthesize rigid pseudomycin side-chain analogs without compromising in vitro antifungal activity.

IT **139203-13-7**, Pseudomycin A **139203-14-8**, Pseudomycin B **139203-15-9**, Pseudomycin C
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(preparation and antifungal activity of pseudomycin side-chain analogs)

RN 139203-13-7 HCAPLUS
CN Pseudomycin A (9CI) (CA INDEX NAME)



RN 139203-14-8 HCAPLUS
CN Pseudomycin B (9CI) (CA INDEX NAME)



RN 139203-15-9 HCAPLUS
CN Pseudomycin C (9CI) (CA INDEX NAME)



IT **307498-30-2P 307498-31-3P 307498-32-4P**
307498-33-5P 307498-34-6P 307498-35-7P
307498-52-8P 307498-53-9P 307498-54-0P
307498-75-5P 307498-76-6P 307498-77-7P
307498-78-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antifungal activity of pseudomycin side-chain analogs)

RN 307498-30-2 HCAPLUS

CN Pseudomycin A, 1-[N-[(3S)-3-hydroxy-3-(3-octylphenyl)-1-oxopropyl]-L-serine]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 307498-31-3 HCAPLUS
CN Pseudomycin A, 1-[N-[(3S)-3-(3-dodecylphenyl)-3-hydroxy-1-oxopropyl]-L-serine]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 307498-32-4 HCAPLUS
CN Pseudomycin A, 1-[N-[(3S)-3-hydroxy-1-oxo-3-[3-(undecyloxy)phenyl]propyl]-L-serine]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 307498-33-5 HCAPLUS
CN Pseudomycin A, 1-[N-[(3R)-3-hydroxy-3-(3-octylphenyl)-1-oxopropyl]-L-serine]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 1-B



PAGE 2-A



RN 307498-34-6 HCAPLUS
CN Pseudomycin A, 1-[N-[(3R)-3-(3-dodecylphenyl)-3-hydroxy-1-oxopropyl]-L-serine]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 1-B



PAGE 2-A



RN 307498-35-7 HCAPLUS
CN Pseudomycin A, 1-[N-[(3R)-3-hydroxy-1-oxo-3-[3-(undecyloxy)phenyl]propyl]-L-serine]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 1-B



PAGE 2-A



RN 307498-52-8 HCAPLUS
CN Pseudomycin A, 1-[N-[3-hydroxy-4-[3-(octyloxy)phenyl]-1-oxobutyl]-L-serine]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 307498-53-9 HCAPLUS
CN Pseudomycin A, 1-[N-[4-[3-(hexyloxy)phenyl]-3-hydroxy-1-oxobutyl]-L-serine]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 307498-54-0 HCAPLUS
CN Pseudomycin A, 1-[N-[4-[3-(decyloxy)phenyl]-3-hydroxy-1-oxobutyl]-L-serine]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 307498-75-5 HCAPLUS
CN Pseudomycin A, 1-[N-[(3R)-3-hydroxy-1-oxo-5-[3-(pentyloxy)phenyl]pentyl]-L-serine]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 1-B



PAGE 2-A



RN 307498-76-6 HCAPLUS
CN Pseudomycin A, 1-[N-[(3S)-3-hydroxy-1-oxo-5-[3-(pentyloxy)phenyl]pentyl]-L-serine]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 1-B



PAGE 2-A



RN 307498-77-7 HCAPLUS
CN Pseudomycin A, 1-[N-[5-[3-(heptyloxy)phenyl]-3-hydroxy-1-oxopentyl]-L-serine]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 307498-78-8 HCAPLUS
CN Pseudomycin A, 1-[N-[3-hydroxy-5-[3-(nonyloxy)phenyl]-1-oxopentyl]-L-serine]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 1-B



PAGE 2-A



IT **307498-27-7P 307498-28-8P 307498-29-9P**
307498-49-3P 307498-50-6P 307498-51-7P
307498-69-7P 307498-70-0P 307498-71-1P
307498-72-2P 307498-74-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and antifungal activity of pseudomycin side-chain analogs)

RN 307498-27-7 HCAPLUS

CN Pseudomycin A, 1-[N-[3-hydroxy-3-(3-octylphenyl)-1-oxopropyl]-L-serine]-2-[(2R)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]-4-[N6-[(phenylmethoxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B



PAGE 1-C



RN 307498-28-8 HCAPLUS
CN Pseudomycin A, 1-[N-[3-(3-dodecylphenyl)-3-hydroxy-1-oxopropyl]-L-serine]-2-[(2R)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]-4-[N6-[(phenylmethoxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B



PAGE 1-C



RN 307498-29-9 HCAPLUS
CN Pseudomycin A, 1-[N-[3-hydroxy-1-oxo-3-[3-(undecyloxy)phenyl]propyl]-L-serine]-2-[(2R)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]-4-[N6-[(phenylmethoxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B



PAGE 1-C



RN 307498-49-3 HCAPLUS
CN Pseudomycin A, 1-[N-[3-hydroxy-4-[3-(octyloxy)phenyl]-1-oxobutyl]-L-serine]-2-[(2R)-2-amino-4-[[(2-propenyloxy)carbonyl]amino]butanoic acid]-4-[N6-[(2-propenyloxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(2-propenyloxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C





RN 307498-50-6 HCAPLUS
CN Pseudomycin A, 1-[N-[4-[3-(hexyloxy)phenyl]-3-hydroxy-1-oxobutyl]-L-serine]-2-[(2R)-2-amino-4-[[(2-propenyloxy)carbonyl]amino]butanoic acid]-4-[N6-[(2-propenyloxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(2-propenyloxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B



PAGE 1-C



RN 307498-51-7 HCAPLUS
CN Pseudomycin A, 1-[N-[4-[3-(decyloxy)phenyl]-3-hydroxy-1-oxobutyl]-L-serine]-2-[(2R)-2-amino-4-[[(2-propenyloxy)carbonyl]amino]butanoic acid]-4-[N6-[(2-propenyloxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(2-propenyloxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 307498-69-7 HCAPLUS
CN Pseudomycin A, 1-[N-[3-hydroxy-1-oxo-5-[3-(pentyloxy)phenyl]pentyl]-L-serine]-2-[(2R)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]-4-[N6-[(phenylmethoxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 307498-70-0 HCAPLUS
CN Pseudomycin A, 1-[N-[(3R)-3-hydroxy-1-oxo-5-[3-(pentyloxy)phenyl]pentyl]-L-serine]-2-[(2R)-2-amino-4-[[(2-propenyloxy)carbonyl]amino]butanoic acid]-4-[N6-[(2-propenyloxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(2-propenyloxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 307498-71-1 HCAPLUS

CN Pseudomycin A, 1-[N-[(3S)-3-hydroxy-1-oxo-5-[3-(pentyloxy)phenyl]pentyl]-L-serine]-2-[(2R)-2-amino-4-[[(2-propenyloxy)carbonyl]amino]butanoic acid]-4-[N6-[(2-propenyloxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(2-propenyloxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 307498-72-2 HCAPLUS
CN Pseudomycin A, 1-[N-[5-[3-(heptyloxy)phenyl]-3-hydroxy-1-oxopentyl]-L-serine]-2-[(2R)-2-amino-4-[[(2-propenyloxy)carbonyl]amino]butanoic acid]-4-[N6-[(2-propenyloxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(2-propenyloxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 307498-74-4 HCAPLUS
CN Pseudomycin A, 1-[N-[3-hydroxy-5-[3-(nonyloxy)phenyl]-1-oxopentyl]-L-serine]-2-[(2R)-2-amino-4-[[(2-propenyloxy)carbonyl]amino]butanoic acid]-4-[N6-[(2-propenyloxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(2-propenyloxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L59 ANSWER 21 OF 26 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:269124 HCAPLUS
DOCUMENT NUMBER: 133:59075
TITLE: Serendipitous synthesis of novel dehydro- and dechloro-pseudomycin B (PSB) derivatives
AUTHOR(S): Zhang, Yanzhi; Boyer, Robert; Sun, Xicheng; Paschal, Jonathan; Chen, Shu-Hui
CORPORATE SOURCE: A Division of Eli Lilly and Company, Lilly Corporate Center, Lilly Research Laboratories, Indianapolis, IN, 46285, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2000), 10(8), 775-778
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 133:59075
AB The syntheses and preliminary investigation of antifungal activities of two dehydro PSB derivs. as well as one 3-imido-9-dechloro PSB analog are described.
IT **139203-14-8P,** Pseudomycin B
RL: BSU (Biological study, unclassified); PNU (Preparation, unclassified); BIOL (Biological study); PREP (Preparation)
(preparation and antifungal activity of dehydro- and dechloro-pseudomycin B derivs.)
RN 139203-14-8 HCAPLUS

CN Pseudomycin B (9CI) (CA INDEX NAME)



IT **277758-37-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation and antifungal activity of dehydro- and dechloro-pseudomycin B derivs.)

RN 277758-37-9 HCAPLUS

CN Pseudomycin B, 2-[(2R)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]-4-[N6-[(phenylmethoxy)carbonyl]-L-lysine]-5-[(2S)-2-amino-4-[[(phenylmethoxy)carbonyl]amino]butanoic acid]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B



PAGE 1-C



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L59 ANSWER 22 OF 26 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:711608 HCAPLUS
DOCUMENT NUMBER: 130:77315
TITLE: Solution conformation of the Pseudomonas syringae MSU 16H phytotoxic lipodepsipeptide pseudomycin A determined by computer simulations using distance geometry and molecular dynamics from NMR data
AUTHOR(S): Coiro, Vincenza Maria; Segre, Anna Laura; Di Nola, Alfredo; Paci, Maurizio; Grottesi, Alessandro; Veglia,

Gianluigi; Ballio, Alessandro
CORPORATE SOURCE: Istituto di Strutturistica Chimica "G. Giacomello", CNR, Montelibretti, Rome, Italy
SOURCE: European Journal of Biochemistry (1998), 257(2), 449-456
CODEN: EJBCAI; ISSN: 0014-2956
PUBLISHER: Springer-Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Pseudomycin A is a cyclic lipodepsinonapeptide phytotoxin produced by a strain of the plant pathogenic bacterium P. syringae. Like other members of this family of bacterial metabolites, it is characterized by a fatty acylated cyclic peptide with mixed chirality and lactonic closure. Several biol. activities of pseudomycin A are lower than those found for some of its congeners, a difference which might depend on the diverse number and distribution of charged residues in the peptide moiety. Hence, it was of interest to investigate its conformation in solution After the complete interpretation of the 2-dimensional NMR spectra, NOE data were obtained and the structure was determined by computer simulations, applying distance geometry and mol. dynamics procedures. The conformation of the large ring of pseudomycin A in solution includes 3 rigid structural regions interrupted by 3 short flexible regions that act as hinges. The overall 3-dimensional structure of the cyclic moiety is similar to that of previously studied bioactive lipodepsinonapeptides produced by other pseudomonads.
IT **139203-13-7**, Pseudomycin A
RL: PRP (Properties)
(solution conformation of Pseudomonas syringae MSU 16H phytotoxic lipodepsipeptide pseudomycin A determined by computer simulations using distance geometry and mol. dynamics from NMR data)
RN 139203-13-7 HCAPLUS
CN Pseudomycin A (9CI) (CA INDEX NAME)



REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L59 ANSWER 23 OF 26 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:478225 HCAPLUS
DOCUMENT NUMBER: 127:91566
TITLE: Biological activities of pseudomycin A, a lipodepsinonapeptide from Pseudomonas syringae MSU 16H
AUTHOR(S): Di Giorgio, Domenico; Camoni, Lorenzo; Marchiafava,

Camilla; Ballio, Alessandro
CORPORATE SOURCE: Dipartimento di Scienze Biochimiche "A. Rossi-Fanelli" e Centro di Biologia Molecolare del CNR, Universita "La Sapienza", Rome, Italy
SOURCE: Phytochemistry (1997), 45(7), 1385-1391
CODEN: PYTCAS; ISSN: 0031-9422
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Similarly to other Pseudomonas lipodepsinonapeptides, pseudomycin A inhibits proton extrusion from maize roots, promotes closure of stomata in Vicia faba, necrosis of tobacco leaves, hemolysis of human erythrocytes, affects H+-ATPase activity and proton translocation in plasma membrane vesicles, and stimulates succinate respiration in pea mitochondria. In general, the biol. activities of pseudomycin A are lower than those of syringomycin-E, the prototype member of this family of bacterial metabolites. This difference might depend on the diverse number and distribution of charged residues in the peptide moiety of these compds.
IT **139203-13-7**, Pseudomycin A
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(phytotoxic activities of)
RN 139203-13-7 HCAPLUS
CN Pseudomycin A (9CI) (CA INDEX NAME)



L59 ANSWER 24 OF 26 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1996:713650 HCAPLUS
DOCUMENT NUMBER: 126:54850
TITLE: Peptides from Pseudomonas syringae possessing broad-spectrum antibiotic activity
INVENTOR(S): Strobel, Gary A.; Harrison, Leslie A.; Teplow, David B.
PATENT ASSIGNEE(S): Research and Development Institute, Inc. At Montana State University, USA
SOURCE: U.S., 28 pp., Cont.-in-part of U.S. Ser. No. 982,687, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5576298	A	19961119	US 1994-305943	19940915
US 5837685	A	19981117	US 1996-673775	19960627
US 5981264	A	19991109	US 1998-13923	19980127

PRIORITY APPLN. INFO.:
US 1992-982687 19921130
US 1994-305943 19940915
US 1996-673775 19960627

AB Peptide antimycotics, termed pseudomycins, display broad spectrum antibiotic activity, and in particular are highly effective, non-toxic antibiotics against fungal pathogens of human and animal disease. The peptide antimycotics (pseudomycins) may be used in the treatment of the fungal pathogen Candida albicans. Also disclosed is a method of purification and isolation, including characterization, of the pseudomycins.

IT **139203-13-7P**, Pseudomycin A **139203-14-8P**, Pseudomycin B **139203-15-9P**, Pseudomycin C
RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pseudomycin peptides from Pseudomonas syringae with antibiotic activity)

RN 139203-13-7 HCAPLUS
CN Pseudomycin A (9CI) (CA INDEX NAME)



RN 139203-14-8 HCAPLUS
CN Pseudomycin B (9CI) (CA INDEX NAME)



RN 139203-15-9 HCAPLUS
CN Pseudomycin C (9CI) (CA INDEX NAME)



IT **162443-73-4**, Pseudomycin C'
RL: PRP (Properties)
(pseudomycin peptides from Pseudomonas syringae with antibiotic activity)
RN 162443-73-4 HCAPLUS
CN Pseudomycin C' (9CI) (CA INDEX NAME)



L59 ANSWER 25 OF 26 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:232029 HCAPLUS
DOCUMENT NUMBER: 122:234902
TITLE: Novel bioactive lipodepsipeptides from Pseudomonas syringae: the pseudomycins
AUTHOR(S): Ballio, A.; Bossa, F.; Di Giorgio, D.; Ferranti, P.; Paci, M.; Pucci, P.; Scaloni, A.; Segre, A.; Strobel, G. A.
CORPORATE SOURCE: Dipartimento di Scienze Biochimiche 'A. Rossi Fanelli' e Centro di Biologia Molecolare del CNR, Universita 'La Sapienza', Roma, 00185, Italy
SOURCE: FEBS Letters (1994), 355(1), 96-100
CODEN: FEBLAL; ISSN: 0014-5793
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The covalent structure and most of the stereochem. of the pseudomycins, bioactive metabolites of a transposon-generated mutant of a P. syringae wild-type strain proposed for the biol. control of Dutch elm disease, were determined While 2 pseudomycins are identical to the known syringopeptins 25-A and 25-B, pseudomycins A, B, C, and C' are new lipodepsinonapeptides. For all of these the peptide moiety corresponds to L-Ser-D-Dab-L-Asp-L-Lys-L-Dab-L-aThr-Z-Dhb-L-Asp(3-OH)-L-Thr(4-Cl), with the terminal carboxyl group closing a macrocyclic ring on the OH group of the N-terminal Ser. This is in turn N-acylated by 3,4-dihydroxytetradecanoate in pseudomycin A, by 3-hydroxytetradecanoate in pseudomycin B, by 3,4-dihydroxyhexadecanoate in pseudomycin C, and by 3-hydroxyhexadecanoate in pseudomycin C'. Some preliminary data on the biol. activity of pseudomycin A are reported.

IT **139203-13-7**, Pseudomycin A
RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
(pseudomycins, novel bioactive lipodepsipeptides from Pseudomonas syringae)
RN 139203-13-7 HCAPLUS
CN Pseudomycin A (9CI) (CA INDEX NAME)



IT **139203-14-8**, Pseudomycin B **139203-15-9**, Pseudomycin C
162443-73-4, Pseudomycin C'
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
(pseudomycins, novel bioactive lipodepsipeptides from Pseudomonas syringae)
RN 139203-14-8 HCAPLUS
CN Pseudomycin B (9CI) (CA INDEX NAME)



RN 139203-15-9 HCAPLUS
CN Pseudomycin C (9CI) (CA INDEX NAME)



RN 162443-73-4 HCAPLUS
CN Pseudomycin C' (9CI) (CA INDEX NAME)



L59 ANSWER 26 OF 26 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1992:80065 HCAPLUS
DOCUMENT NUMBER: 116:80065
TITLE: Pseudomycins, a family of novel peptides from Pseudomonas syringae possessing broad-spectrum antifungal activity
AUTHOR(S): Harrison, Leslie; Teplow, David B.; Rinaldi, Michael; Strobel, Gary
CORPORATE SOURCE: Dep. Plant Pathol., Montana State Univ., Bozeman, MT, 59717, USA
SOURCE: Journal of General Microbiology (1991), 137(12), 2857-65
CODEN: JGMIAN; ISSN: 0022-1287
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A family of peptide antimycotics, termed pseudomycins, was isolated from liquid cultures of P. syringae, a plant-associated bacterium. These compds. were purified using Amberlite XAD-2 and reverse-phase liquid chromatog.

Pseudomycin A, the predominant peptide in a family of 4, showed selective phytotoxicity and had impressive activity against the human pathogen Candida albicans. Amino acid, mass spectroscopic, and comparative electrophoretic and chromatog. analyses revealed that the pseudomycins are different from previously described antimycotics from P. syringae, including syringomycin, syringotoxin, and syringostatins. Pseudomycins A-C contain hydroxyaspartic acid, aspartic acid, serine, arginine, lysine, and diaminobutyric acid. The mol. masses of pseudomycins A-C, as determined by plasma desorption mass spectrometry, are 1224, 1208, and 1252 Da, resp. Pseudomycin D, on the other hand, has a mol. mass of 2401 Da and is more complex than pseudomycins A-C.

IT **139203-13-7**, Pseudomycin A **139203-14-8**, Pseudomycin B
139203-15-9, Pseudomycin C
RL: BIOL (Biological study)
(antifungal antibiotic, from Pseudomonas syringae)

RN 139203-13-7 HCAPLUS
CN Pseudomycin A (9CI) (CA INDEX NAME)



RN 139203-14-8 HCAPLUS
CN Pseudomycin B (9CI) (CA INDEX NAME)



RN 139203-15-9 HCAPLUS

CN Pseudomycin C (9CI) (CA INDEX NAME)



=> d que stat l59
L54 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 61

STEREO ATTRIBUTES: NONE
L56 179 SEA FILE=REGISTRY SSS FUL L54
L57 26 SEA FILE=HCAPLUS ABB=ON L56
L58 7 SEA FILE=HCAPLUS ABB=ON L57 AND ?PRODRUG?
L59 26 SEA FILE=HCAPLUS ABB=ON L57 OR L58

```
=> d his ful

     FILE 'REGISTRY' ENTERED AT 15:32:45 ON 26 MAY 2004
L6                STRUCTURE
L7                STR
                  E PSEUDOMYCIN/CN
L8              1 SEA ABB=ON  "PSEUDOMYCIN A"/CN
L9                STRUCTURE
L10             9 SEA SSS SAM L9
L11           197 SEA SSS FUL L9

     FILE 'HCAPLUS' ENTERED AT 16:00:50 ON 26 MAY 2004
L12           115 SEA ABB=ON  L11

     FILE 'REGISTRY' ENTERED AT 16:01:23 ON 26 MAY 2004
L13               STR L9
L14             9 SEA SSS SAM L13
                  DIS L13
L15               STR L13
L16               STR L13
L17             9 SEA SSS SAM L16

     FILE 'HCAPLUS' ENTERED AT 17:19:59 ON 26 MAY 2004
L18             7 SEA ABB=ON  L12 AND ?PRODRUG?

     FILE 'REGISTRY' ENTERED AT 17:23:23 ON 26 MAY 2004
L19           185 SEA SSS FUL L16
L20               STR L16
L21             0 SEA SSS SAM L20
L22             0 SEA SSS FUL L20
L23               STR L20
L24             0 SEA SSS SAM L23
L25             0 SEA SSS FUL L23
L26               STR L23
L27             9 SEA SSS SAM L26
L28           179 SEA SSS FUL L26
L29               STR L26
L30             9 SEA SSS SAM L29
L31           179 SEA SSS FUL L29
L32               STR L29
L33             0 SEA SSS SAM L32
L34             0 SEA SSS FUL L32
L35               STR L32
L36             0 SEA SSS SAM L35
L37               STR L35
L38             0 SEA SSS SAM L37
L39               STR L37
L40             0 SEA SSS SAM L39
L41             0 SEA SSS FUL L39
L42               STR L39
L43             9 SEA SSS SAM L42
L44           179 SEA SSS FUL L42
L45               STR L42
L46             9 SEA SSS SAM L45
L47           181 SEA SSS FUL L45
L48               STR L42
L49             9 SEA SSS SAM L48
L50           179 SEA SSS FUL L48
L51               STR L39
L52             0 SEA SSS SAM L51
```

```
L53             STR L51
L54             STR L42,DIS
L55           9 SEA SSS SAM L54
L56         179 SEA SSS FUL L54

     FILE 'HCAPLUS' ENTERED AT 18:01:25 ON 26 MAY 2004
L57          26 SEA ABB=ON  L56
L58           7 SEA ABB=ON  L57 AND ?PRODRUG?
L59          26 SEA ABB=ON  L57 OR L58
             SAV L59 MAY654L59/A

     FILE 'REGISTRY' ENTERED AT 18:04:56 ON 26 MAY 2004
             SAV L56 AY654L56/A
```

179 compds from ~~CAS~~ Registry — see 4 gne stds. attached.

26 cits from CA Plus — 7 are for "prodrug"; all 7 are applicants' work